Lupin receives final approval for Celecoxib Capsules

From USFDA

Lupin announced that the Company has received final approval for its Celecoxib Capsules, 50 mg from the United States Food and Drug Administration (USFDA) to market a generic version of G.D. Searle LLC's (a subsidiary of Pifzer Inc.) Celebrex capsules 50 mg. Lupin also received tentative approvals for its Celecoxib capsules 100 mg, 200 mg and 400 mg strengths from the USFDA.

Powered by Capital Market - Live News